Immune to Cancer: The CRI Blog
-
CRI Funded Scientist
Ning Jenny Jiang, PhD
Checkpoint immunotherapy has revolutionized cancer treatment, but only a fraction of patients experience complete responses. “Killer” T cells, which target… -
CRI Funded Scientist
Ivan Zanoni, PhD
The immune system has evolved to protect against infectious viruses and bacteria, and to maintain tissue homeostasis…. -
CRI Funded Scientist
Michael Weinfeld, PhD
Breast cancer is the most common cancer in women in North America, accounting for about 25% of… -
CRI Funded Scientist
Christopher B. Medina, PhD
Dr. Medina is supported by the CRI Irvington Postdoctoral Fellowship to Promote Racial Diversity. T cells are immune… -
CRI Funded Scientist
Enrico Lugli, PhD
T cells can protect against tumor development, but can become progressively dysfunctional or “exhausted” as cancers progress,… -
CRI Funded Scientist
Cheryl Ho, MD
Dr. Cheryl Ho is a medical oncologist at Vancouver Cancer Centre. She is one of two study chairs for the… -
CRI Funded Scientist
Anna Tinker, MD
Dr. Anna Tinker is a medical oncologist at Vancouver Cancer Centre. She is one of two study chairs for… -
CRI Funded Scientist
Helen MacKay, MD
Dr. Helen Mackay is the head of the Division of Medical Oncology and Hematology at Odette Cancer Centre Sunnybrook Health… -
CRI Funded Scientist
Dmitriy Zamarin, MD, PhD
Dr. Dmitriy Zamarin is a medical oncologist at Memorial Sloan Kettering Cancer Center. He is the study…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.